Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model

被引:44
作者
Alici, Evren [1 ]
Konstantinidis, Kyriakos V. [1 ]
Sutlu, Tolga [1 ]
Aints, Alar [1 ]
Gahrton, Gosta [1 ]
Ljunggren, Hans-Gustaf [1 ]
Dilber, M. Sirac [1 ]
机构
[1] Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Med, Ctr Infect Med, S-14186 Stockholm, Sweden
关键词
D O I
10.1016/j.exphem.2007.08.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Despite advances in autologous stem cell transplantation and chemotherapy, multiple myeloma (MM) remains an incurable disease. Due to the role of natural killer (NK) cells in host resistance against several tumors, it is of interest to explore the anti-MM activity of NK cells. For this reason, we aimed to determine if NK cells provide anti-MM activity following interleukin-2 (IL-2) administration, and if ex vivo activated and intravenously administered NK cells prolong survival in MM-bearing C57BL/KaLwRij mice. Methods. The anti-MM effect of IL-2 was tested by intraperitoneal injection into the 5T33MM-inoculated mice. Subsequently, in vivo effector cell depletions were performed by administration of anti-NK1.1 or anti-CD8 monoclonal antibodies. Finally, magnetically separated and activated NK cells from splenocytes of C57BL/KaLwRij mice were adoptively transferred to tumor-bearing mice in conjunction with IL-2 treatment. Results. IL-2 administration into MM-bearing mice significantly prolonged their survival. This effect was diminished by in vivo depletion of NK cells. Adoptive transfer of activated NK cells showed a significant in vivo anti-MM effect that was dependent on cell dose. Biodistribution of the marked adoptively transferred NK cells correlated with MM cells' homing sites. Conclusion. These data suggest that activated NK cells have a promising potential in adoptive immunotherapy for MM. (C) 2007 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc.
引用
收藏
页码:1839 / 1846
页数:8
相关论文
共 32 条
  • [1] Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: Establishment of a new syngeneic murine model of multiple myeloma
    Alici, E
    Konstantinidis, KV
    Aints, A
    Dilber, MS
    Abedi-Valugerdi, M
    [J]. EXPERIMENTAL HEMATOLOGY, 2004, 32 (11) : 1064 - 1072
  • [2] Cutting edge:: The mouse NK cell-associated antigen recognized by DX5 moncoclonal antibody is CD49b (α2 integrin, very late antigen-2)
    Arase, H
    Saito, T
    Phillips, JH
    Lanier, LL
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 167 (03) : 1141 - 1144
  • [3] Asea A, 1998, IMMUNOLOGY, V93, P296
  • [4] A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
    Attal, M
    Harousseau, JL
    Stoppa, AM
    Sotto, JJ
    Fuzibet, JG
    Rossi, JF
    Casassus, P
    Maisonneuve, H
    Facon, T
    Ifrah, N
    Payen, C
    Bataille, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) : 91 - 97
  • [5] High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
    Child, JA
    Morgan, GJ
    Davies, FE
    Owen, RG
    Bell, SE
    Hawkins, K
    Brown, J
    Drayson, MT
    Selby, PJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (19) : 1875 - 1883
  • [6] Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma:: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT
    Crawley, C
    Lalancette, M
    Szydlo, R
    Gilleece, M
    Peggs, K
    Mackinnon, S
    Juliusson, G
    Ahlberg, L
    Nagler, A
    Shimoni, A
    Sureda, A
    Boiron, JM
    Einsele, H
    Chopra, R
    Carella, A
    Cavenagh, J
    Gratwohl, A
    Garban, F
    Zander, A
    Björkstrand, B
    Niederwieser, D
    Gahrton, G
    Apperley, JF
    [J]. BLOOD, 2005, 105 (11) : 4532 - 4539
  • [7] Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
    Davies, FE
    Raje, N
    Hideshima, T
    Lentzsch, S
    Young, G
    Tai, YT
    Lin, B
    Podar, K
    Gupta, D
    Chauhan, D
    Treon, SP
    Richardson, PG
    Schlossman, RL
    Morgan, GJ
    Muller, GW
    Stirling, DI
    Anderson, KC
    [J]. BLOOD, 2001, 98 (01) : 210 - 216
  • [8] ALLOGENEIC BONE-MARROW TRANSPLANTATION IN MULTIPLE-MYELOMA
    GAHRTON, G
    TURA, S
    LJUNGMAN, P
    BELANGER, C
    BRANDT, L
    CAVO, M
    FACON, T
    GRANENA, A
    GORE, M
    GRATWOHL, A
    LOWENBERG, B
    NIKOSKELAINEN, J
    REIFFERS, JJ
    SAMSON, D
    VERDONCK, L
    VOLIN, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (18) : 1267 - 1273
  • [9] Progress in hematopoietic stem cell transplantation in multiple myeloma
    Gahrton, S
    [J]. CURRENT OPINION IN HEMATOLOGY, 2005, 12 (06) : 463 - 470
  • [10] LYMPHOKINE-ACTIVATED KILLER CELL PHENOMENON - LYSIS OF NATURAL KILLER-RESISTANT FRESH SOLID TUMOR-CELLS BY INTERLEUKIN 2-ACTIVATED AUTOLOGOUS HUMAN PERIPHERAL-BLOOD LYMPHOCYTES
    GRIMM, EA
    MAZUMDER, A
    ZHANG, HZ
    ROSENBERG, SA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1982, 155 (06) : 1823 - 1841